Eli Lilly and Company: Lung Neoplasms trials
The registry lists 24 Lung Neoplasms studies with Eli Lilly and Company as lead sponsor. 2 are open to participants now and 13 have results posted.
Phase 1 6Phase 2 17Phase 3 3No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Sofe-M in Participants With Selected Advanced Solid TumorsRecruitingNCT06400472Phase 1
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Phase 3
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/2Results posted
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/2Results posted
- A Study in Non-Small Cell Lung CancerCompletedNCT01232452Phase 2Results posted
- A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based ChemotherapyCompletedNCT01168973Phase 3Results posted
- A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01160744Phase 2Results posted
- Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung CancerCompletedNCT01109524Phase 2Results posted
- Study of Participants With Advanced Non-Small Cell Lung CancerCompletedNCT00948675Phase 3Results posted
- A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00918203Phase 2Results posted
- Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + PlaceboTerminatedNCT00538681Phase 2Results posted
- An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using PemetrexedCompletedNCT00497770Results posted
- A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former SmokersCompletedNCT00414960Phase 2Results posted
- Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC TumorTerminatedNCT00356525Phase 2Results posted
- Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or AbdomenCompletedNCT00316225Phase 2Results posted
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT06561685Phase 1
- A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT02941601Phase 2
- A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and PaclitaxelWithdrawnNCT00768131Phase 2
- Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00071136Phase 1/2
- ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.CompletedNCT00051506Phase 2
- ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.CompletedNCT00051493Phase 2
- A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.CompletedNCT00042679Phase 2
- Comparing 3 Schedules of Alimta Plus GemzarCompletedNCT00034606Phase 2